Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicriviroc plus optimized background therapy versus placebo in treatment-experienced adults with CCR5-tropic HIV-1
2005-001247-39Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Vicriviroc + OBT with Placebo + OBT (2 arms). Primary endpoints: Change in plasma HIV-1 RNA AAUCMB at Week 24 and Change in plasma HIV-1 RNA AAUCMB at Week 48. Started Jun 2005; status: completed.
02
Drugs
vicriviroc
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2005-001247-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001247-39.